Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches

Geert Spierenburg(Leiden University Medical Center), Hans Gelderblom(Leiden University Medical Center), Kirsten van Langevelde(Leiden University Medical Center), Károly Szuhai(Leiden University Medical Center), Judith V.M.G. Bovée(Leiden University Medical Center), L. van der Heijden(Leiden University Medical Center), Michiel A. J. van de Sande(Leiden University Medical Center)
Expert Opinion on Therapeutic Targets
April 3, 2022
10.1080/14728222.2022.2067040
Cited by 30

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k